Rising health insurance premiums and deductibles are intensifying pressure on households, with prescription drug costs once again emerging as a focal point of the affordability debate. As the White House promotes a new initiative known as Trump RX to align U.S. drug prices with those paid abroad, questions remain about how much relief the program will actually deliver and whether more consequential reforms are being overlooked.
Dan Proft spoke with C. Steven Tucker, founder of Health Insurance Mentors, about what the Trump RX rollout means for consumers navigating an increasingly complex insurance landscape. Tucker argued that while the initiative may raise awareness about existing discount options, it does not fundamentally change the pricing dynamics that already exist in the private market.
According to Tucker, many of the discounts highlighted by Trump RX mirror those long available through private platforms such as GoodRx, which negotiate lower cash prices directly with pharmacies. In some cases, he noted, patients can achieve similar or better savings by appealing directly to pharmaceutical manufacturers, a process that often results in free or deeply discounted medications for insured and uninsured patients alike. Tucker said Trump RX’s primary value may lie in educating consumers who were previously unaware of these options rather than delivering new price reductions.
More significant, Tucker contended, are two policy changes he said are poised to have a near-term impact. One involves Medicare coverage of GLP-1 weight-loss drugs. Under current rules, Medicare Part D generally requires a diagnosis such as diabetes before covering these medications. Tucker said a forthcoming change will allow broader coverage, potentially reducing monthly out-of-pocket costs from hundreds or thousands of dollars to modest copays for many seniors.
The second development centers on reforms targeting pharmacy benefit managers, or PBMs, the intermediaries that negotiate drug prices and rebates on behalf of insurers. Tucker said recently enacted federal changes will require PBMs to pass rebates through to plans instead of retaining them, a practice critics argue has inflated prices for brand-name and specialty drugs. He characterized the shift as a structural reform that could lower costs across employer-sponsored, individual, and Medicare plans.
The conversation also turned to ongoing turmoil in the Affordable Care Act marketplace, particularly in Illinois. Tucker described widespread problems with Get Covered Illinois, the state-run enrollment platform that replaced the federal exchange for Illinois residents. He said technical failures have left some consumers without active coverage despite having paid premiums, exposing them to significant financial risk if they experience a medical emergency. Tucker attributed the disruption to the state’s decision to move off the federal system, a change he said was driven by policy preferences but has resulted in serious administrative breakdowns.
Taken together, the discussion painted a picture of a health insurance system under strain, where headline initiatives like Trump RX may generate attention but do little to address deeper cost drivers. Tucker argued that meaningful relief is more likely to come from changes to coverage rules and middleman incentives, while warning that administrative failures at the state level can quickly erase any savings consumers might otherwise see.